
Quantum BioPharma Advances IND Application for Lucid-MS with Final Toxicity Reports
Quantum BioPharma has received final toxicity reports for Lucid-MS, supporting its IND application to the FDA for a Phase 2 clinical trial of this potential breakthrough multiple sclerosis treatment.
Read full story
























